AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03398031
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
Trial: NCT01347541
Drug: FDA-Approved Anti-Anxiety Medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
Trial: NCT01656005
Drug: Beclometasone
RxNorm normalized name: Beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs bid for final week (week 6) of each treatment arm
Trial: NCT00796731
Drug: SAR3419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by intravenous infusion
Trial: NCT03951831
Drug: REGN2810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
Trial: NCT00253773
Drug: acetominophen, sulfer amino acids; cysteine and methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03718884
Drug: Drug Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
Trial: NCT04130230
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for sepsis and septic shock
Trial: NCT00382421
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01794663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion for 1 hour at start of transplant procedure
Trial: NCT00350870
Drug: disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg per day of Disulfiram plus CBT
Trial: NCT00350870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus CBT
Trial: NCT00350870
Drug: Disulfiram plus Contingency Management
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
Trial: NCT03136146
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03783442
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT03783442
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT03783442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Tislelizumab
Trial: NCT00675623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for six months
Trial: NCT01527279
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
Trial: NCT00323492
Drug: Current HAART regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain baseline regimen
Trial: NCT00093899
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 6 months
Trial: NCT03042429
Drug: Cycles N8, N5 and N6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two chemotherapy cycles N8 followed by standard arm therapy
Trial: NCT01480583
Drug: GRN1005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 mg/m2 IV every 3 weeks
Trial: NCT02620800
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
Trial: NCT02620800
Drug: calcium leucovorin
RxNorm normalized name: Calcium leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
Trial: NCT02997696
Drug: Placebo matching ONO-4474
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01555970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
Trial: NCT01130909
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg
Trial: NCT01130909
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg
Trial: NCT01130909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mL sterile NaCl 0.9%
Trial: NCT03989349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00943098
Drug: Diclofenac HPBCD s.c. 75mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single injection at day of dental surgical extraction
Trial: NCT00943098
Drug: Voltarol 75mg/3ml i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single injection at day of dental surgical extraction
Trial: NCT03404063
Drug: Cardiac Drug
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group.
Trial: NCT03404063
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.
Trial: NCT02524275
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00050206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02065843
Drug: Mulungu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/single dose/1 hour before dental surgery
Trial: NCT02065843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/single dose/1 hour before dental surgery
Trial: NCT00420082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated Placebo tablets Q.D.
Trial: NCT03515733
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, identical appearance to experimental tablet
Trial: NCT04041544
Drug: SN1011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
Trial: NCT04041544
Drug: SN1011 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
Trial: NCT00729495
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose form
Trial: NCT02850419
Drug: ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
Trial: NCT03315793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01787396
Drug: Placebo(Metformin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01787396
Drug: Placebo(Gemigliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712983
Drug: TIP
RxNorm normalized name: Q-Tips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIP dose regimen
Trial: NCT02712983
Drug: TIP and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIP and inhaled placebo dose regimen
Trial: NCT02712983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo dose regimen
Trial: NCT03173976
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
Trial: NCT00283803
Drug: Antiandrogen
RxNorm normalized name: Antiandrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
Trial: NCT00479505
Drug: UK-369,003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
Trial: NCT00479505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02428751
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Trial: NCT02428751
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Trial: NCT00721760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Trial: NCT02679144
Drug: Difluoromethylornithine (DFMO)
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
Trial: NCT00559455
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
Trial: NCT00559455
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m², Day 1 and Day 2; Every 2 weeks
Trial: NCT00093197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03883347
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
Trial: NCT01340625
Drug: Norethindrone/Ethinyl Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/35 mcg Chewable Tablets
Trial: NCT01340625
Drug: Ovcon® 35 Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/35 mcg Chewable Tablets
Trial: NCT01162954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00182715
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00182715
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00182715
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00053976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00606541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01110330
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Trial: NCT04925076
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
Trial: NCT01361763
Drug: Antiplatelets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg once a day
Trial: NCT00368381
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
Trial: NCT03388866
Drug: Mite extract sublingual immunotherapy (SLIT)
RxNorm normalized name: mite extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
Trial: NCT03321981
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same endocrine therapy is administered as the last line of endocrine therapy
Trial: NCT01360645
Drug: Placebo + ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + FDA Approved Antidepressant (ADT)
Trial: NCT02834117
Drug: moderate ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
Trial: NCT02377752
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03462017
Drug: SAR247799
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Trial: NCT03462017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Trial: NCT03462017
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution Route of administration: Transdermal
Trial: NCT01811485
Drug: LMF237 50/250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
Trial: NCT01811485
Drug: LMF237 50/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
Trial: NCT01811485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
Trial: NCT01062555
Drug: Prograf & Cellcept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Trial: NCT03516773
Drug: EB612 (EBP05)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entera Bio's proprietary drug for the administration of PTH(1-34) orally
Trial: NCT03516773
Drug: NATPARA/NATPAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
Trial: NCT02427386
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
Trial: NCT02570724
Drug: injection of HES  Voluven® 
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
Trial: NCT01062555
Drug: Rapamune and Cellcept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Trial: NCT03984890
Drug: Traditional treatment of CGD and TB
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis drugs, interferon-gamma
Trial: NCT02018536
Drug: GSK2336805 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Trial: NCT02018536
Drug: GSK2336805 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Trial: NCT02018536
Drug: GSK2336805 120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Trial: NCT02018536
Drug: GSK2336805 60 mg (Treatment B and part of Treatment C and D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
Trial: NCT02018536
Drug: TMC435 100 mg (part of Treatment C)
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
Trial: NCT02018536
Drug: TMC435 150 mg (part of treatment D)
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
Trial: NCT03617536
Drug: CR845 0.25 mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 0.25 mg medication taken orally 1 time/day
Trial: NCT03617536
Drug: CR845 0.5 mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 0.5 mg medication taken orally 1 time/day
Trial: NCT03617536
Drug: CR845 1 mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 1 mg medication taken orally 1 time/day
Trial: NCT03617536
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally 1 time/day
Trial: NCT01117298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab Placebo every alternate day for 8 weeks
Trial: NCT01555073
Drug: pregabalin/celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
Trial: NCT01555073
Drug: celecoxib/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
Trial: NCT01555073
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Trial: NCT02003794
Drug: 0.9% NaCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
Trial: NCT01731158
Drug: TKI: Sutent, Nexavar or Votrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI
Trial: NCT00000487
Drug: antihypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000487
Drug: diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01049204
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 24 weeks
Trial: NCT00939029
Drug: placebo NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo patches (containing no active ingredient)per day for 8 weeks
Trial: NCT01496326
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10% ibuprofen cream formulation at a dose of 200mg
Trial: NCT01496326
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams of placebo cream for 14 days
Trial: NCT02091362
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02091362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally